Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (121-130 of 189) with videos related to

Pageof 19
Sort By:
Plos One|January 13, 2012
Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafishSteven L Walker, Junko Ariga, Jonathan R Mathias, et al.
Autophagy|January 30, 2010
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cellsSudharsan Periyasamy-Thandavan, William H Jackson, Julia S Samaddar, et al.
Cancers|December 10, 2021
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell NeoplasmC Cameron Yin, Naveen Pemmaraju, M James You, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Oncotarget|July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsKyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
Blood Cancer Journal|February 1, 2022
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cellsWarren Fiskus, Taghi Manshouri, Christine Birdwell, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Cancer Research|August 10, 2016
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing AgentsWarren Fiskus, Veena Coothankandaswamy, Jianguang Chen, et al.
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Pageof 19

Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Plos One|January 13, 2012
Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafishSteven L Walker, Junko Ariga, Jonathan R Mathias, et al.
Autophagy|January 30, 2010
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cellsSudharsan Periyasamy-Thandavan, William H Jackson, Julia S Samaddar, et al.
Cancers|December 10, 2021
Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell NeoplasmC Cameron Yin, Naveen Pemmaraju, M James You, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Leukemia|December 22, 2019
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentEkaterina Kim, Elisa Ten Hacken, Mariela Sivina, et al.
Oncotarget|July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsKyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
Blood Cancer Journal|February 1, 2022
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cellsWarren Fiskus, Taghi Manshouri, Christine Birdwell, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Cancer Research|August 10, 2016
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing AgentsWarren Fiskus, Veena Coothankandaswamy, Jianguang Chen, et al.
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Pageof 19